Synercid is a combination of 30 parts Quinupristin and 70 parts Dalfopristin, which are considered semisynthetic streptogramin antibiotics (macromolecular antibiotics produced by Streptomyces pristinaepiralis) and together, the compounds act synergistically as each is bacteriostatic, but Synercid is bactericidal. Synercid also inhibits the isoenzyme cytochrome P450-3A4. Synercid is derived from Pristinamycin (Quinupristin is derived from pristinamycin IA; dalfopristin from pristinamycin IIA). The compound was developed 1989 by Rhône-Poulenc (France).
Synercid is soluble in water.